COCP - Cocrystal Pharma updates on COVID-19 antiviral development programs

Cocrystal Pharma (COCP) announces progress in developing broad-spectrum antiviral drug candidates that COVID-19. In December 2020, Cocrystal selected CDI-45205 as its lead coronavirus development candidate under an exclusive license agreement with Kansas State University Research Foundation. CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and also no cytotoxicity against a variety of human cell lines.Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice. Cocrystal has obtained promising preliminary pharmacokinetic results and is continuing to further evaluate CDI-45205. Cocrystal has leveraged its antiviral development expertise by using its proprietary technology and drug discovery platform to launch a second COVID-19 program with additional antiviral compounds developed. “Lead discovery and optimization are ongoing. We anticipate identifying another SARS-CoV-2 preclinical lead for oral administration this year. In addition to these two SARS-CoV-2 protease programs, we are also developing

For further details see:

Cocrystal Pharma updates on COVID-19 antiviral development programs